Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the SURFAST Care Pathway.

N/ANot Yet RecruitingNCT07417982

Assistance Publique - Hôpitaux de Paris1,000 enrolled

Overview

Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres. At Assistance Publique-Hôpitaux de Paris, a multidisciplinary reference network called the SURFAST consortium has been established. This network includes experts in the management of NSTIs, such as intensivists, dermatologists, infectious disease physicians, paediatricians, surgeons, and microbiologists. The consortium manages all NSTI cases referred from the greater Paris area, a large region of France with a population exceeding 12 million. The SURFAST network comprises care pathways enabling the management of adult and paediatric patients with abdomino-perineal, limb, and cervico-facial NSTIs. All patients managed within this care pathway are included in a prospective, multicentre cohort study. This study examines factors associated with mortality at day 90, long-term sequelae, quality of life, and indicators of the quality of care.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Necrotizing Soft-tissue Infections

Eligibility

Sex: ALLMin age: 0 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients (adults and children, irrespective of age) managed for suspected or surgically confirmed necrotizing soft-tissue infections (NSTI) • Consent to participate in the study Exclusion Criteria: * Patient or legal representative's refusal to participate in the study

Locations (1)

Outcomes

Primary Outcomes

mortality

If the patient is still hospitalized, an on-site visit will be conducted; otherwise, the patient or their relative will be contacted by telephone by an investigator or a study coordinator

Time frame: 90 days

Secondary Outcomes

hospital mortality

vital status measured at hospital discharge

Time frame: at hospital discharge and within 60 days of hospital admission

time from hospital admission to first surgical debridement

time period measured in hours between first hospital admission and first surgical debridement

Time frame: within the first 72 hours of hospital admission

functional outcome and quality of life

measured using the Activity of Daily Living (ADL) and the EQ-5D-5L (EuroQol) French version scores

Time frame: day 90 post-admission

amputation rate

toe or limb amputation performed

Time frame: day 90

annual case volume per centre

number of NSTI cases managed per year in each centre participating in the SURFAST network

Time frame: 123 months

bacteriological documentation

bacterial documentation of NSTIs obtained from blood cultures or cultures of operative tissue samples.

Time frame: At the time of blood culture collection or operative tissue sampling